BR112023013052A2 - Anticorpo monoclonal contra mac-1 humano e seus usos - Google Patents

Anticorpo monoclonal contra mac-1 humano e seus usos

Info

Publication number
BR112023013052A2
BR112023013052A2 BR112023013052A BR112023013052A BR112023013052A2 BR 112023013052 A2 BR112023013052 A2 BR 112023013052A2 BR 112023013052 A BR112023013052 A BR 112023013052A BR 112023013052 A BR112023013052 A BR 112023013052A BR 112023013052 A2 BR112023013052 A2 BR 112023013052A2
Authority
BR
Brazil
Prior art keywords
mac
against human
monoclonal antibody
antibody against
human mac
Prior art date
Application number
BR112023013052A
Other languages
English (en)
Inventor
Chia-Ming Chang
Wen-Chi Lee Frank
I-Fang Tsai
Ping-Yen Huang
Yen-Ta Lu
Original Assignee
Ascendo Biotechnology Inc
Frank Wen Chi Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendo Biotechnology Inc, Frank Wen Chi Lee filed Critical Ascendo Biotechnology Inc
Publication of BR112023013052A2 publication Critical patent/BR112023013052A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

anticorpo monoclonal contra mac-1 humano e seus usos. são fornecidos anticorpos monoclonais contra mac-1 humano. esses anticorpos podem se ligar a diferentes estados do mac-1, de modo a alterar as biofunções do mac-1. esses anticorpos podem modular as secreções de citocina th1/th2 por células imunes ativadas por tlr e podem ser usados para o tratamento de doenças relacionadas a distúrbios inflamatórios agudos e crônicos, como doenças infecciosas e cânceres.
BR112023013052A 2020-12-30 2021-12-30 Anticorpo monoclonal contra mac-1 humano e seus usos BR112023013052A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063131893P 2020-12-30 2020-12-30
PCT/US2021/065802 WO2022147338A1 (en) 2020-12-30 2021-12-30 Monoclonal antibody against human mac-1 and uses thereof

Publications (1)

Publication Number Publication Date
BR112023013052A2 true BR112023013052A2 (pt) 2023-09-26

Family

ID=82259686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023013052A BR112023013052A2 (pt) 2020-12-30 2021-12-30 Anticorpo monoclonal contra mac-1 humano e seus usos

Country Status (10)

Country Link
US (1) US20240084017A1 (pt)
EP (1) EP4271413A1 (pt)
JP (1) JP2024501884A (pt)
KR (1) KR20230140448A (pt)
CN (1) CN116963772A (pt)
AU (1) AU2021413899A1 (pt)
BR (1) BR112023013052A2 (pt)
CA (1) CA3203552A1 (pt)
TW (1) TW202325340A (pt)
WO (1) WO2022147338A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444101A1 (en) * 2010-10-21 2012-04-25 Universitätsklinikum Freiburg Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
SG11201509899PA (en) * 2013-06-26 2016-01-28 Numab Ag Novel antibody frameworks
EP3194437B1 (en) * 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use

Also Published As

Publication number Publication date
CA3203552A1 (en) 2022-07-07
US20240084017A1 (en) 2024-03-14
AU2021413899A1 (en) 2023-08-03
JP2024501884A (ja) 2024-01-16
KR20230140448A (ko) 2023-10-06
TW202325340A (zh) 2023-07-01
CN116963772A (zh) 2023-10-27
EP4271413A1 (en) 2023-11-08
WO2022147338A1 (en) 2022-07-07

Similar Documents

Publication Publication Date Title
EA201591754A1 (ru) Человеческие антитела к na1.7
NL300914I2 (nl) Atezolizumab
MY169165A (en) Anti-pdgfr-beta antibodies and uses thereof
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
WO2019094642A8 (en) T cell manufacturing compositions and methods
EA201790377A1 (ru) Антитела к глюкагону и их применения
AR090585A1 (es) Anticuerpos anti-hla-b*27 y usos de estos
PE20161217A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201690905A1 (ru) Специфические антитела против cd38 для лечения злокачественных новообразований у человека
GEP20217263B (en) Anti-cd27 antibodies
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
AR118859A1 (es) Composiciones y métodos de fabricación de células t
EA201491452A1 (ru) Антитела к asic1 и их применение
BRPI0516661A (pt) epitopos antigênicos da interleucina-21, anticorpos relacionados e seu uso no campo medicinal
EA201991203A1 (ru) Способы лечения ожирения антителами к angptl8
CR20180097A (es) Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
HRP20220419T1 (hr) Terapija matičnim stanicama kod patologija endometrija
PH12019502617A1 (en) Antibody-cytokine engrafted proteins and methods of use for immune related disorders
AR104361A1 (es) Terapia de combinación de anticuerpo que se une a angiopoyetina 2 con anticuerpo que se une al ligando 1 de muerte programada
BR112023013052A2 (pt) Anticorpo monoclonal contra mac-1 humano e seus usos
EA202090947A1 (ru) Композиции и способы для истощения cd5+ клеток
EA201690321A1 (ru) Применение иммуноконъюгата антитела к muc1 и майтанзиноида для лечения солидных опухолей